- Celltrion will supply its COVID-19 treatment without profit margin in S. Korea.
- Celltrion’s CT-P59 began to be supplied to local medical institutions on Wednesday.
- The company has also planned to supply the treatment globally after keeping enough for all Koreans.
- Celltrion is said to be in talks with the U.S Food and Drug Administration.
Tags : SOUTH KOREA PHARMACEUTICAL COMPANY, CELLTRION, COVID-19 TREATMENT, CELLTRION CT-P59, CELLTRION CHAIRMAN, SEO JUNG JIN,